RxDoctor Payments Data

Jennifer Grant, APRN

Family · Henderson, NVNPI 1265131965

Payments from drug & device makers

$767in general payments, 2019–2025

Across 20 payments — averaging $38.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$281
  • Lilly USA, LLC$138
  • Novo Nordisk$117
  • Boehringer Ingelheim$49
  • Amgen$41
  • Phathom Pharmaceuticals, Inc.$41
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 65th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$1,167
Medicare patients
12
Services billed
13

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin29$35,036
OzempicSemaglutide18$22,681
MounjaroTirzepatide14$19,866
EliquisApixaban17$18,540
FarxigaDapagliflozin Propanediol20$14,326
Levothyroxine Sodium106$871
Atorvastatin Calcium109$855
Gabapentin40$820
Triamcinolone Acetonide14$721
Losartan Potassium68$652
Ventolin HfaAlbuterol Sulfate11$630
Albuterol Sulfate HfaAlbuterol Sulfate30$471
Omeprazole38$448
Metformin Hcl83$434
Pravastatin Sodium39$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$49$35,03629 claims
Novo NordiskOzempic$117$22,68118 claims
Lilly USA, LLCMounjaro$138$19,86614 claims
PfizerEliquis$17$18,54017 claims
AstraZenecaFarxiga$281$14,32620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →